


La biologia del carcinoma mammario: comprendere i meccanismi molecolari per individuarne le vulnerabilità

Andrea Morandi

Università degli Studi di Padova 20 Dicembre 2022


WHAT IS BREAST CANCER?

• 11.7% of cancer cases diagnosed in adults in 2020 were breast cancer (Worldwide), 24.5% in women. This is 2,261,419 cases.



• breast cancer incidence is strongly related to age


• female breast cancer death rates have fallen by 40% in the UK






Age at Diagnosis


6.9% of cancer deaths in adults in 2020 were breast cancer (Worldwide), 15.5% in women.
This is 684,996 cases.



All breast cancers arise in the terminal duct lobular units (the functional unit of the breast) of the collecting duct




Mechanism and Pathophysiology



Nature Reviews | Cancer

Breast Cancer under the microscope



Predict behaviour

- histological types
- grade
- size
- lymph node status

Cancer biology

- hormone receptors
- HER2
- proliferation

Histological subtypes

Preinvasive

Ductal carcinoma in situ (DCIS)

 Spreads through ducts and distorts ductal architecture; can progress to invasive cancer; unilateral

Lobular carcinoma in situ (LCIS)

- Does not distort ductal architecture; can be bilateral
- Risk factor rather than precursor

Invasive

Ductal carcinoma no special type (NST)


 Develops from DCIS; fibrous response to produce a mass; metastasizes via lymphatics and blood

Lobular carcinoma (ILC)


 Isolated tumor cells (CDH1 mutations) minimal fibrous response; metastasizes preferentially via viscera

Breast cancer is a family of diseases

Diversity of breast tumour subtypes



Perou et al, Nature 2000; Sørlie T et al. PNAS 2001



Histological subtypes

Preinvasive

Ductal carcinoma in situ (DCIS)

 Spreads through ducts and distorts ductal architecture; can progress to invasive cancer; unilateral

Lobular carcinoma in situ (LCIS)

- Does not distort ductal architecture; can be bilateral
- Risk factor rather than precursor

Luminal **B**

PI3KCA mutations (40%); ESR1 mutations (30–40%)^a; ERBB2 and ERBB3 mutations; NST, micropapillary and atypical lobular histology

Invasive

Ductal carcinoma no special type (NST)


- Develops from DCIS; fibrous response to produce a mass; metastasizes via lymphatics and blood
- Lobular carcinoma (ILC)
- Isolated tumor cells (CDH1 mutations) minimal fibrous response; metastasizes preferentially via viscera

Luminal A

Activation of ERS1, GATA3, FOXA1, XBP1; NST, tubular cribriform and classic lobular histology


Comprehensive molecular portraits of human breast tumours

The Cancer Genome Atlas Network*



>50% of mutations are present in < 10% of breast cancer


TCGA, Nature 2012



Surrogate intrinsic subtypes	Triple-negative ER–, PR–, HER2–; high grade; high Ki67 index; NST histology; special type histology (metaplastic, adenoid cystic, medullary-like and secretory); poor prognosis except for some special types	HER2-enriched (non-luminal) ER–, PR–, HER2+; high grade; high Ki67 index; NST histology; aggressive disease but responds to targeted therapies; intermediate prognosis	Luminal B-like HER2+ ER+ but lower ER and PR expression than luminal A-like; HER2+; higher grade; high Ki67 index; NST and pleiomorphic; responds to targeted therapies; intermediate prognosis	Luminal B-like HER2– ER+ but ER and PR expression lower than in luminal A-like; HER2–; higher grade; high Ki67 index; high-risk GES; NST, micropapillary and lobular pleiomorphic histology; intermediate prognosis	Luminal A-like Strongly ER+ and PR+; HER2–; low proliferation rates; typically low grade; low Ki67 index; low-risk GES; NST, tubular cribriform and classic lobular histology; good prognosis
	10-15%	13–1	15%	10-20%	60–70%
	Proliferation				
	High grade				
	Basal-like genes				ER expression
		HER2 expression			Low grade

Harbeck et al, Nature Reviews 2019


Breast cancer progression (theory vs real life)



Microinvasion

Invasive Cancer


ER+ breast cancers




- 2/3 of breast cancers are ER+
- Endocrine therapy is the standard of care for these cancers


Her2-Positive

Breast Cancer






ADC in HER2 positive cancer – mechanism of action



HER2 EXPRESSION IN BC


~15% HER2-~85% HER2-negative positive (IHC 0, IHC 1+, or IHC 2+/ISH-) ~60% ~40% IHC 0 of patients with HER2-negative BC have low levels of HER2 expression (IHC 1+ or IHC 2+/ISH-)^{1,2}

Destiny Breast04 – Trial Efficacy in HR+/HER2-low mBC



Modi et al, *NEJM* 2022

>6 months longer overall survival vs chemotherapy



Modi et al, NEJM 2022

Basal (Triple Negative) Breast Cancer


ER, PR, HER2 negative

High nuclear grade and proliferative index


BRCA1/2 positive


Chemosensitive (but poor prognosis)

TNT: Carboplatin vs Docetaxel in Advanced TNBC or *BRCA1/2*+ BC




- Primary endpoint: ORR in ITT population
- Secondary endpoints: PFS, OS, ORR (crossover), toxicity
- Subgroup analyses: BRCA1/2 mutation, basal-like subgroups, HRD biomarkers






A Progression-free Survival



Olaparib 205 201 177 159 154 129 107 100 94 73 69 61 40 36 23 0 0 Standard therapy 97 88 63 46 44 29 25 24 21 13 11 11


Robson et al., NEJM 2017





Tutt et al., NEJM 2021


Immune crosstalk in breast cancer





Harbeck et al, Nature Reviews 2019

The NEW ENGLAND JOURNAL of MEDICINE

Pembrolizumab for Triple-Negative Breast Cancer







In all luminal-like tumours: adjuvant endocrine therapy (minimum 5 years; if high-risk, extended for up to 7–10 years)^a

• Premenopausal women: tamoxifen; if high-risk: GnRH analogue and tamoxifen or aromatase inhibitor

• Postmenopausal women: aromatase inhibitor and/or tamoxifen upfront or in sequence with each other


• Under investigation: CDK4/6 inhibitor plus endocrine therapy


In postmenopausal women or premenopausal women receiving ovarian suppression

Consider adjuvant bisphosphonates

Harbeck et al, Nature Reviews 2019


Common metastatic sites in breast cancer






Harbeck et al, Nature Reviews 2019

Therapeutic Options




Mechanisms of therapy resistance




Cancer Cell 37, April 13, 2020

Mechanisms of therapy resistance and therapeuti approaches





Cancer Cell 37, April 13, 2020

Therapeutic options – Palbociclib (CDK4/6i)



Clinical trials showing superior outcome in patients treated with a combination of ET and a CDK4/6 inhibitor





| Censored observations


Abemaciclib arm: median, not reached

Placebo arm: median, 19.2 months


No. at Risk

Palbociclib-444 395 360 328 295 263 238 154 69 29 10 2 Letrozole Placebo-222 171 148 131 116 98 81 54 22 12 4 2 Letrozole

MONALEESA2



MONALEESA7



Finn et al, NEJM 2016; Hortobagyi et al, NEJM 2016; Di Leo et al, JCO 2017; Tripathy et al, Lancet Oncol 2018

MONARCH3

100


90 80

70

60


50

Mechanisms of therapy resistance



Morandi and Isacke, *Breast Can Res* 2014 Morandi *et al.*, *Cancer Research* 2013 Plaza-Menacho, Morandi et al., *JBC* 2011 Plaza-Menacho, Morandi *et al.*, *Oncogene* 2010 Morandi *et al., Trends Mol Med* 2011 Mologni et al., *MCE* 2013 Andreucci, Francica,..., Morandi *Oncotarget* 2016

Targeting the engine and not the drivers of resistance



Metabolic targeting agents in cancer therapy

TABLE 1. Cancer Therapies/Drugs That Target Metabolic Pathways

METABOLIC PATHWAY	TARGET ^a	DRUG	STAGE OF DEVELOPMENT	REFERENCES
Nucleic acid synthesis	Thymidylate synthase (TS)	5-Fluorouracil, capecitabine, pemetrexed, raltitrexed	Approved	Heidelberger 1957, ⁹⁷ Jackman 1991, ⁹⁸ Chin 1997, ⁹⁹ Miwa 1998 ¹⁰⁰
	Dihydrofolate reductase (DHFR)	Methotrexate, pemetrexed	Approved	Chin 1997, ⁹⁹ Myer 1950, ¹⁰¹ Wright 1951 ¹⁰²
	Glycinamide ribonucleotide formyltransferase (GARFT)	Pemetrexed	Approved	Chin 1997 ⁹⁹
	Dihydroorotate dehydrogenase (DHODH)	Brequinar, leflunomide	Phase 1/2	Sykes 2018 ¹⁰³
	Ribonucleotide reductase (RNR)	Gemcitabine, clofarabine, fludarabine, cladribine, cytarabine	Approved	Xie & Plunkett 1996, ¹⁰⁴ Heinemann 1990, ¹⁰⁵ Greene 2020, ¹⁰⁶ Evans 1961, ¹⁰⁷ Hertel 1990 ¹⁰⁸
	5-Phosphoribosyl-1-pyro-phosphatase (PRPP) amidotransferase	Mercaptopurine, thioguanine	Approved	Skipper 1954, ¹⁰⁹ Atkinson & Murray 1965, ¹¹⁰ Hill & Bennett 1969 ¹¹¹
Glycolysis	GLUT1	WZB117, BAY-876	Preclinical	Ma 2018, ¹¹² Liu 2012 ¹¹³
	Hexokinase	2-Deoxyglucose	Phase 1/2	Dwarakanath 2009 ¹¹⁴
	Pyruvate Kinase M2 (PKM2)	TEPP-46	Preclinical	Anastasiou 2012 ¹¹⁵
	Lactate dehydrogenase A (LDHA)	Quinoline, 3-sulfonamides, FX11, PSTMB	Preclinical	Kim 2019, ¹¹⁶ Billiard 2013, ¹¹⁷ Le 2010 ¹¹⁸
	Monocarboxylate transporter 1 (MCT1)	AZD3965	Phase 1	Marchiq & Pouyssegur 2016 ¹¹⁹
Glutamine metabolism	Glutaminase 1 (GLS1)	CB-839, IPN60090	Phase 1/2	Xiang 2015, ¹²⁰ Gross 2014, ¹²¹ Soth 2020 ¹²²
	ASCT2 (SLC1A5)	GPNA	Preclinical	Yoo 2020, ¹²³ Esslinger 2005 ¹²⁴
	Multiple targets	JHU-083	Preclinical	Leone 2019, ⁹⁵ Hanaford 2019 ¹²⁵
Amino acid transport and	Phosphoglycerate dehydrogenase (PHGDH)	CBR-5884, NCT-503	Preclinical	Wang 2017, ¹²⁶ Pacold 2016, ¹²⁷ Mullarky 2016 ¹
biosynthesis	Indoleamine-2,3-dioxygenase-1 (IDO1)	Epacadostat, indoximod	Phase 3	Prendergast 2017 ¹²⁹
	Circulating asparagine	L-Asparaginase	Approved	Clavell 1986 ¹³⁰
	Large neutral amino acid transporter (LAT1)	JPH203	Preclinical	Enomoto 2019, ¹³¹ Oda 2010 ¹³²
Mitochondrial metabolism	Pyruvate dehydrogenase (PDH), α -ketoglutarate dehydrogenase	CPI-613	Phase 2	Zachar 2011 ¹³³
	Electron transport chain complex 1	Metformin, IACS-010759	Phase 1-3	Molina 2018, ¹³⁴ Yam 2019 ¹³⁵
Lipid metabolism	ATP-citrate lyase (ACLY)	SB-204990	Preclinical	Hatzivassiliou 2005, ¹³⁶ Shah 2016 ¹³⁷
	Acetyl-CoA carboxylase (ACC)	Soraphen-A	Preclinical	Svensson 2016, ¹³⁸ Corominas 2014 ¹³⁹
	fatty acid synthase (FASN)	TVB-2640	Phase 2	Mullen & Yet 2015 ¹⁴⁰
Enzymes mutated in cancer	Mutant isocitrate dehydrogenase 1 (IDH1)	AG-120, BAY1436032, LY3410738, FT-2102	Phase 1-3	DiNardo 2018, ¹⁴¹ Heuser 2020 ¹⁴²
	Mutant isocitrate dehydrogenase 2 (IDH2)	AG-221	Phase 3	Stein 2017 ¹⁴³

^aKey targets of nucleoside analogs are shown; however, most nucleoside analogs inhibit multiple nucleic acid and DNA synthesis/repair enzymes, including DNA polymerase.


CA A Cancer J Clinicians, Volume: 71, Issue: 4, Pages: 333-358, First published: 13 May 2021, DOI: (10.3322/caac.21670)

Fasting-mimicking diet and hormone therapy induce breast cancer regression


MCF7


https://doi.org/10.1038/s41586-020-2502-7		
Received: 25 November 2018		
Accepted: 30 April 2020		
Published online: 15 July 2020		
le Check for updates		


Irene Caffa^{1,14}, Vanessa Spagnolo^{2,3,14}, Claudio Vernieri^{3,4}, Francesca Valdemarin^{1,5}, Pamela Becherini^{1,5}, Min Wei⁶, Sebastian Brandhorst⁶, Chiara Zucal⁷, Else Driehuis^{8,9}, Lorenzo Ferrando⁵, Francesco Piacente^{1,5}, Alberto Tagliafico¹⁰, Michele Cilli¹, Luca Mastracci^{1,11}, Valerio G. Vellone^{1,11}, Silvano Piazza⁷, Anna Laura Cremonini^{1,5}, Raffaella Gradasch¹¹, Carolina Mantero¹, Mario Passalacqua¹², Alberto Ballestreo¹⁵, Gabriele Zoppoli^{1,5}, Michele Cea^{1,5}, Annalisa Arrighi⁵, Patrizio Odetti^{1,5}, Fiammetta Monacelli^{1,8}, Giulia Salvadori^{2,3}, Salvatore Cortellino³, Hans Clevers^{8,8,13}, Filippo De Braud^{2,4}, Samir G. Sukkar¹, Alessandro Provenzani⁷, Valter D. Longo^{3,6,15}²² &



Patient no. 26 (second-line treatment for HR⁺/HER2⁻ mBC with FULV + PALB + FMD)







Nature 2020 Jul;583(7817):620-624.

nature reviews cancer

Explore content ~ About the journal ~ Publish with us ~

nature > nature reviews cancer > review articles > article

Review Article Published: 25 May 2022

Developing dietary interventions as therapy for cancer

Samuel R. Taylor, John N. Falcone, Lewis C. Cantley & Marcus D. Goncalves

Nature Reviews Cancer (2022) Cite this article

18 Altmetric Metrics

